Alto Neuroscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ANRO New York 2834 www.altoneuroscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alto Neuroscience, Inc.

All You Need to Know About Alto Neuroscience, Inc. (ANRO) Rating Upgrade to Buy - Jan 8th, 2025 5:00 pm
Alto Neuroscience Announces Data Presented at the 63rd Annual Meeting of the American College of Neuropsychopharmacology - Dec 11th, 2024 1:03 pm
Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights - Nov 12th, 2024 9:10 pm
Alto Neuroscience to Participate in Upcoming Investor Conferences - Nov 4th, 2024 1:00 pm
Wedbush downgrades Alto Neuroscience to Neutral following ALTO-100 readout - Oct 24th, 2024 12:32 pm
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform - Oct 23rd, 2024 5:36 pm
Alto hits new low as depression drug flunks key test - Oct 23rd, 2024 12:03 pm
Alto’s Phase IIb study of ALTO-100 for MDD fails to meet primary endpoint - Oct 23rd, 2024 11:32 am
Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder - Oct 22nd, 2024 8:30 pm
Alto Neuroscience Insiders Placed Bullish Bets Worth US$638.5k - Sep 11th, 2024 1:08 pm
15 Healthiest Countries in Asia - Sep 5th, 2024 1:27 pm
Alto Neuroscience Announces Peer-Reviewed Publication in the Journal of Clinical Psychiatry Demonstrating Baseline Cognitive Performance is Not a Moderator of Response to Standard-of-Care Antidepressants - Sep 4th, 2024 12:05 pm
Alto Neuroscience Reports Second Quarter 2024 Financial Results and Recent Business Highlights - Aug 13th, 2024 8:05 pm
institutional investors of Alto Neuroscience, Inc. (NYSE:ANRO) must be disappointed after last week's 26% drop - Aug 1st, 2024 1:11 pm
Alto Neuroscience Receives Funding Award from Wellcome Trust to Accelerate Development of ALTO-100 in Bipolar Depression Leveraging Precision Psychiatry Approach - Jul 25th, 2024 12:30 pm
Alto Neuroscience Announces Enrollment Completion in Phase 2b Study of ALTO-100 in Major Depressive Disorder - Jul 16th, 2024 11:30 am
Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia - Jun 20th, 2024 12:05 pm
Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner - Jun 18th, 2024 12:05 pm
Alto Neuroscience to Present at the Jefferies Global Healthcare Conference - May 29th, 2024 12:05 pm
Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer - May 21st, 2024 12:05 pm